Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma

Fujiwara,Yoshinori; Yoshikawa,Reigetsu; Kamikonya,Norihiko; Nakayama,Tsuyoshi; Kitani,Kotaro; Tsujie,Masanori; Yukawa,Masao; Hara,Johji; Yamamura,Takehira; Inoue,Masatoshi

doi:10.3892/mco.2013.128

Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma

Authors:
- Yoshinori Fujiwara
- Reigetsu Yoshikawa
- Norihiko Kamikonya
- Tsuyoshi Nakayama
- Kotaro Kitani
- Masanori Tsujie
- Masao Yukawa
- Johji Hara
- Takehira Yamamura
- Masatoshi Inoue
View Affiliations

Affiliations: Department of Digestive Surgery, Nara Hospital, Kinki University School of Medicine, Ikoma, Nara 630‑0293, Japan, Department of Surgery, Kanzaki Hospital, Amagasaki, Hyogo 661‑0967, Japan, Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan
Published online on: May 21, 2013 https://doi.org/10.3892/mco.2013.128
Pages: 773-779

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to improve the survival of esophageal cancer patients, a trimodality therapy consisting of esophagectomy in combination with neoadjuvant chemoradiotherapy (CRT) has been developed. In this study, we evaluated whether neoadjuvant CRT improved the outcomes of patients with resectable esophageal squamous cell carcinoma (ESCC) compared to surgery alone. Eighty‑eight patients with resectable ESCC were treated with either neoadjuvant CRT followed by surgical resection (Group A, n=52), or surgery alone (Group B, n=36). CRT consisted of 5‑fluorouracil (5‑FU, 500 mg/m2 on days 1‑5) and cisplatin (CDDP, 10‑20 mg/kg body weight on days 1‑5), repeated after 3 weeks. Survival analysis was performed using the log‑rank test with the Kaplan‑Meier method. The clinical response of the primary tumor and metastatic nodes was 80.8%. The postoperative complications profile was similar between the two groups, except for anastomotic leakage. The median survival time (MST) was not reached in Group A and was 27.4 months in Group B. The estimated 5‑year overall survival (OS) rate was 50.3% in Group A and 39.9% in Group B (P=0.134). As regards stage II̸III disease, Group A exhibited a better disease‑free survival (DFS) compared to Group B (5‑year DFS: 57.2% in Group A vs. 31.4% in Group B; P=0.025). Simultaneous locoregional and distant recurrences were more common in the surgery alone group (Group B, P=0.047). Neoadjuvant CRT with 5‑FU and CDDP did not contribute to a better prognosis in patients with resectable ESCC. However, it may be beneficial for patients with stage II̸III disease.

View Figures

View References

1.	GLOBOCAN 2008, All Cancers (excluding non-melanoma skin cancer) Incidence and Mortality Worldwide. Available: http://globocan.iarc.fr/factsheets/cancers/all.asp. Accessed August 26, 2012.
2.	Cancer Statistics in Japan-2011. Available: http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed August 26, 2012.
3.	Goseki N, Koike M and Yoshida M: Histopathologic characteristics of early stage esophageal carcinoma. A comparative study with gastric carcinoma. Cancer. 69:1088–1093. 1992. View Article : Google Scholar : PubMed/NCBI
4.	Roth JA and Putnam JB Jr: Surgery for cancer of the esophagus. Semin Oncol. 21:453–461. 1994.PubMed/NCBI
5.	Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T and Okudaira Y: Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet. 157:537–540. 1983.PubMed/NCBI
6.	Karl RC, Schreiber R, Boulware D, Baker S and Coppola D: Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg. 231:635–643. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Orringer MB, Marshall B and Iannettoni MD: Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 230:392–403. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Chu KM, Law SY, Fok M and Wong J: A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg. 174:320–324. 1997. View Article : Google Scholar : PubMed/NCBI
9.	Lieberman MD, Shriver CD, Bleckner S and Burt M: Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg. 109:130–139. 1995. View Article : Google Scholar : PubMed/NCBI
10.	Ellis FH Jr, Heatley GJ, Krasna MJ, Williamson WA and Balogh K: Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg. 113:836–848. 1997.
11.	Isono K, Sato H and Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 48:411–420. 1991. View Article : Google Scholar : PubMed/NCBI
12.	Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surgery. 232:225–232. 2000.PubMed/NCBI
13.	Altorki N and Skinner D: Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg. 234:581–587. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Lerut T, Nafteux P, Moons J, et al: Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 240:962–974. 2004. View Article : Google Scholar
15.	Lerut T, Coosemans W, Decker G, et al: Extended surgery for cancer of the esophagus and gastroesophageal junction. J Surg Res. 117:58–63. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Altorki NK, Girardi L and Skinner DB: En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg. 114:948–956. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Collard JM: Exclusive radical surgery for esophageal adenocarcinoma. Cancer. 91:1098–1104. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Clark GW, Peters JH, Ireland AP, et al: Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. Ann Thorac Surg. 58:646–654. 1994. View Article : Google Scholar : PubMed/NCBI
19.	Chen G, Wang Z, Liu XY and Liu FY: Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 31:1107–1114. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T and Hatakeyama K: Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 198:205–211. 2004. View Article : Google Scholar
21.	Matsubara T, Ueda M, Takahashi T, Nakajima T and Nishi M: Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg. 182:340–346. 1996.PubMed/NCBI
22.	Bhansali MS, Fujita H, Kakegawa T, et al: Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 21:275–281. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Hulscher JB, van Sandick JW, Tijssen JG, Obertop H and van Lanschot JJ: The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 191:143–148. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Kyriazanos ID, Tachibana M, Shibakita M, et al: Pattern of recurrence after extended esophagectomy for squamous cell carcinoma of the esophagus. Hepatogastroenterology. 50:115–120. 2003.PubMed/NCBI
25.	Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I and Triboulet JP: Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 97:1616–1623. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 220:364–373. 1994. View Article : Google Scholar : PubMed/NCBI
27.	Kato H, Watanabe H, Tachimori Y and Iizuka T: Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg. 51:931–935. 1991. View Article : Google Scholar : PubMed/NCBI
28.	Altorki N, Kent M, Ferrara C and Port J: Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 236:177–183. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Urba SG, Orringer MB, Perez-Tamayo C, Bromberg J and Forastiere A: Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer. 69:285–291. 1992. View Article : Google Scholar : PubMed/NCBI
30.	Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467. 1996. View Article : Google Scholar : PubMed/NCBI
31.	Nygaard K, Hagen S, Hansen HS, et al: Pre-operative radio-therapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16:1104–1110. 1992. View Article : Google Scholar
32.	Le Prise E, Etienne PL, Meunier B, et al: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 73:1779–1784. 1994.PubMed/NCBI
33.	Apinop C, Puttisak P and Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 41:391–393. 1994.PubMed/NCBI
34.	Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
35.	Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemo-radiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19:305–313. 2001.PubMed/NCBI
36.	Lee JL, Park SI, Kim SB, et al: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 15:947–954. 2004. View Article : Google Scholar
37.	Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 6:659–668. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar : PubMed/NCBI
39.	Fujiwara Y, Kamikonya N, Inoue T, et al: Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: A preliminary report. Oncol Rep. 14:1177–1182. 2005.PubMed/NCBI
40.	Fujiwara Y, Yoshikawa R, Kamikonya N, et al: Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 28:446–452. 2012.
41.	Sobin LH and Wittekin CH: International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th edition. John Wiley & Sons, Inc.; New York: 1997
42.	Japanese Society for Esophageal Diseases: Guidelines for clinical and pathologic studies on carcinoma of the esophagus. 9th edition. Kanehara & Co., Ltd.; Tokyo: 2001
43.	National Cancer Institute: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed August 28, 2012.
44.	Muller JM, Erasmi H, Stelzner M, Zieren U and Pichlmaier H: Surgical therapy of oesophageal carcinoma. Br J Surg. 77:845–857. 1990. View Article : Google Scholar : PubMed/NCBI
45.	Kakegawa T: Study on rational surgery for thoracic esophageal cancer based on the esophageal lymphatic drainage. Annual Report of the Cancer Research Ministry of Health and Welfare 1990 Tokyo: National Cancer Center; pp. 285–289. 1991, (In Japanese).
46.	Iizuka T: Report of 4th Meeting of ISDE TNM. Research Committee; Kyoto. 1992
47.	Watanabe H, Kato H and Tachimori Y: Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res. 155:123–133. 2000. View Article : Google Scholar : PubMed/NCBI
48.	Ide H: Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) and Long-term Results of Esophagectomy in Japan (1988–1997). 3rd edition. The Japanese Society for Esophageal Disease; Chiba: 2002
49.	Herskovic A, Martz K, al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
50.	Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
51.	Yoshikawa R, Nakano Y, Tao L, et al: Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 98:1670–1674. 2008. View Article : Google Scholar : PubMed/NCBI
52.	Igaki H, Tachimori Y and Kato H: Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg. 239:483–490. 2004. View Article : Google Scholar
53.	Fujita H, Kakegawa T, Yamana H, et al: Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 222:654–662. 1995. View Article : Google Scholar
54.	Ando N, Kato H, Igaki H, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
55.	Kitagawa Y, Ando N, Nakamura K, Shibata T and Fukuda H: The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol. 19:1425–1427. 2012. View Article : Google Scholar : PubMed/NCBI
56.	Ajani JA and Swisher SG: Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol. 19:3–4. 2012.PubMed/NCBI